Teva Pharmaceuticals announced that California’s Desert Oasis Healthcare (DOHC) system has implemented a respiratory patient monitoring programme based on its Digihaler System.

The company designed the programme in collaboration with Rimidi, a clinical management platform, to enhance patient experiences and achieve quality objectives.

The new respiratory patient monitoring programme expands the existing collaboration between the two companies, which was initiated in November last year.

Teva said that implementation of the respiratory monitoring programme in a large health system ensures better availability of resources to the patients to support informed treatment plans.

The pharma company claims that its Digihaler is the first and only smart inhaler system to offer objective data that helps patients and their doctors better support asthma management.

Teva senior vice president, digital health and innovation head Manny Montalvo said: “Through collaborations with partners like Rimidi, we hope to improve the patient continuum of care, leading to a more cost-effective healthcare system.

“More than 34 million Americans live with chronic lung disease, and approximately 25 million people in the US currently have asthma.

“We’re energised by the potential of collaborations like this to drive meaningful differences in how asthma is managed and treated, with the collective vision of one-day predicting asthma attacks before they occur.”

Teva and Rimidi are planning to further expand the programme by teaming up with additional health systems, to reduce high costs, low hospitalisations and improve asthma management.

Through the expanded collaboration, DOHC can identify patients with respiratory conditions, who are using Teva’s Digi haler family of inhalers and are eligible for enrolment through the Rimidi platform.

Teva will provide data from Digihaler System, through Rimidi’s Respiratory Module, to help guide treatment decisions for people with respiratory diseases.

The data integration between smart inhalers and electronic health records (EHR) through the Respiratory Module will support the management of COPD and asthma, said Teva.

Rimidi founder and CEO Lucienne Ide said: “The ability to have a streamlined, comprehensive view of a patient’s health condition allows for more efficient and personalised management.

“Rimidi’s Respiratory Module incorporates clinical decision support tools to help clinicians understand potential reasons behind a patient’s uncontrolled asthma, such as not taking their medication or not taking it properly.”